Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Impax Asset Management Group plc

Impax Asset Management Group plc lifted its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 923.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 63,973 shares of the life sciences company's stock after purchasing an additional 57,723 shares during the quarter. Impax Asset Management Group plc's holdings in Illumina were worth $8,343,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ILMN. Primecap Management Co. CA increased its position in shares of Illumina by 462.5% during the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company's stock valued at $253,514,000 after purchasing an additional 1,997,010 shares during the last quarter. Millennium Management LLC increased its position in Illumina by 305.0% during the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company's stock valued at $155,067,000 after acquiring an additional 1,118,747 shares during the last quarter. Capital World Investors raised its stake in shares of Illumina by 41.1% in the first quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company's stock valued at $378,111,000 after acquiring an additional 801,814 shares during the period. Marshall Wace LLP bought a new stake in shares of Illumina in the 2nd quarter worth about $77,628,000. Finally, Swedbank AB purchased a new position in shares of Illumina during the 1st quarter worth about $99,682,000. Institutional investors own 89.42% of the company's stock.

Analyst Ratings Changes

ILMN has been the subject of several recent analyst reports. Daiwa Capital Markets upgraded Illumina from a "neutral" rating to a "buy" rating and boosted their target price for the company from $120.00 to $154.00 in a research report on Friday, August 16th. Argus upgraded Illumina from a "hold" rating to a "buy" rating and set a $150.00 target price on the stock in a research note on Wednesday, August 28th. Scotiabank decreased their target price on Illumina from $176.00 to $164.00 and set a "sector outperform" rating for the company in a research report on Thursday, August 15th. Piper Sandler reduced their price target on shares of Illumina from $195.00 to $185.00 and set an "overweight" rating on the stock in a research note on Monday, November 11th. Finally, StockNews.com initiated coverage on shares of Illumina in a research report on Thursday, August 29th. They issued a "buy" rating for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Illumina currently has an average rating of "Moderate Buy" and a consensus target price of $164.00.

Illumina Stock Down 5.1 %

NASDAQ ILMN traded down $7.19 on Friday, hitting $135.05. The stock had a trading volume of 4,741,753 shares, compared to its average volume of 2,019,896. The business's fifty day moving average price is $139.66 and its 200 day moving average price is $124.30. The stock has a market cap of $21.42 billion, a price-to-earnings ratio of -13.56 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a 52-week low of $92.69 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same period in the previous year, the business earned $0.33 EPS. The firm's revenue for the quarter was down 3.5% on a year-over-year basis. Equities research analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.